Market Overview

Biogen Up Sharply On Promising Alzheimer's Results

Related BIIB
After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?
Couldn't Make It To Leerink's Global Healthcare Conference? Here Are The Highlights From Day One
This Biotech ETF Looks Primed To Rally Again (Seeking Alpha)

Shares of Biogen Idec Inc (NASDAQ: BIIB) were moving sharply higher Tuesday morning following news that its Alzheimer's drug showed promising results and the company said it would proceed with a late-stage trial.

The drug, BIIB037, reduces beta amyloid in the brain, a key contributor to plaque that factors into Alzheimer's disease. The announcement came at the Deutsche Bank BioFEST conference.

Meg Tirrell of CNBC tweeted several highlights:

Shares of Biogen were trading up 6.1 percent at $327.38.

Posted-In: News Health Care General


Related Articles (BIIB)

View Comments and Join the Discussion!